期刊文献+

葛根素对小鼠的通便作用及其机制研究 被引量:2

Laxative Effect of Puerarin and Its Mechanism in Mice
原文传递
导出
摘要 目的:研究葛根素对便秘小鼠的通便作用,探讨其通便机制。方法:采用复方地芬诺酯制造小鼠便秘模型,观察葛根素对便秘模型小鼠的首次排便时间,12h内排便粒数,粪便性状及重量的影响;采用肠段称重法,观察葛根素对大肠水分吸收的影响;采用PowerLab信号处理系统,观察葛根素对大肠平滑肌活动的影响。结果:①三个剂量组与便秘模型组相比,小鼠首次排便时间明显缩短(P<0.05),12h内粪便粒数、重量明显增加(P<0.05),并呈剂量效应。②低、中剂量组与便秘模型组相比,大肠含水量明显增加(P<0.05),高剂量组以上指标不但明显高于便秘模型组(P<0.05),而且明显高于空白对照组(P<0.05)。③与单纯给予复方地芬诺酯相比,葛根素进一步降低了小鼠大肠平滑肌收缩幅度、频率和曲线下面积,具有显著差异性(P<0.05)。结论:葛根素具有通便作用,其机制可能是葛根素增加肠道水分促肠运动的作用大于它对肠道运动的直接抑制作用。 Objective:To investigate the laxative effect of Puerarin on constipation in mice, and to explore the involved mechanism. Methods: Constipation model was established by diphenoxylate. After the constipation model were treated with Puerarin, several factors were observed after Puerarin treated constipation model, including the first defecation time. And the effects of Puerarin on water contents of large intestine and activity of isolated large intestinal smooth muscle were studied by weighing the intestine and Powerlab signal processing system respectively. Results: ① Compared with the model group, Puerarin could shorten the first defecation time and enhance two other factors such as the amount of feces within 12 hours, the weight of feces ( P〈0. 05). ② Compared with model group, low and medium dose of Puerarin could significantly increase the water content in large intestine ( P〈0. 05). And the above factor in high dose Puerarin group is higher than the control and model group ( P〈0.05). ③ Puerarin could further enhance the inhibitory effect of diphenoxylate on the scope , frequency and curve of activities of intestine smooth muscle contraction. Conclusion:Puerarin can defecate feces excretion, whose possible mechanism is that the stimulatory effect by increasing water in intestine is stronger than the direct inhibitory effect on the intestinal activities.
出处 《现代生物医学进展》 CAS 2010年第3期481-483,共3页 Progress in Modern Biomedicine
基金 滨州医学院科技计划(BY2007KJ02)
关键词 葛根素 通便 便秘 Puerarin Laxative Constipation
  • 相关文献

参考文献10

  • 1王靖,吉民,华维一,戴德哉.葛根素研究进展[J].药学进展,2003,27(2):70-73. 被引量:74
  • 2胡静,徐德生.葛根素药理和临床研究进展[J].世界临床药物,2006,27(4):215-220. 被引量:31
  • 3陈文彬.诊断学[M].人民卫生出版社,2003:191-192
  • 4Alaradi O, Barkin JS. Irritable bowel syndrome: update on pathogenesis and management[J]. Med Print Pract, 2002, 11(1):2-17.
  • 5Zhu LH, Wang L, Wang D, etc. Puerarin attenuates high-glucose-and diabetes-induced vascular smooth muscle cell proliferation by blocking PKCbeta2/Racl-dependent signaling [J]. Free Radic Biol Med, 2009.
  • 6Tan Y, Liu M, Wu B. Puerarin for acute ischaemic stroke[J]. Cochrane Database Syst Rev, 2008, 23 (1).
  • 7Li Q, Xiao Y, Gong H, etc. Effect of puerarin on the expression of extraeellular matrix in rats with streptozotocin-induced diabetic nephropathy[J]. Natl Med J India, 2009,22(1): 9-12.
  • 8Pan HP, Li G. Yakugaku Zasshi.Protecting mechanism ofpuerarin on the brain neurocyte of rat in acute local ischemia brain injury and local cerebral ischemia-reperfusion injury. 2008 Nov,128 (11): 1689-98.
  • 9Rembold CM. Regulation of contraction and relaxation inarterial smooth muscle [J ]. Hypertension, 2004,20(2) :129.
  • 10Cao CM, Chen M, Wong TM. The K (Ca) channel as a trigger for the cardioprotection induced by kappa2opioid receptor stimulation its relationship with protein kinase C[J]. Br J Pharmacol, 2005,145(7).

二级参考文献53

共引文献103

同被引文献23

引证文献2

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部